{"id":28616,"date":"2022-09-29T07:44:29","date_gmt":"2022-09-29T07:44:29","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?page_id=28616"},"modified":"2022-09-30T04:32:48","modified_gmt":"2022-09-30T04:32:48","slug":"company-announcements","status":"publish","type":"page","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/","title":{"rendered":"Prescient Therapeutics"},"content":{"rendered":"\n<section id=\"prescient\" class=\"wp-block-gutentor-m3 section-gm600771d gutentor-module gutentor-container-cover has-image-bg has-custom-bg prescient\"><div class=\"grid-container\">\n<section id=\"gm2a47086\" class=\"wp-block-gutentor-m4 section-gm2a47086 gutentor-module gutentor-advanced-columns gutentor-equal-column-height\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmaefe25\" class=\"wp-block-gutentor-m4-col col-gmaefe25 gutentor-single-column  grid-lg-8 grid-md-12 grid-12 wp-col-left\"><div id=\"section-gmaefe25\" class=\"section-gmaefe25 gutentor-col-wrap\">\n<h2 class=\"has-text-color wp-block-heading\" style=\"color:#53d443\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">Prescient Therapeutics<\/mark><\/h2>\n\n\n\n<h3 class=\"has-white-color has-text-color wp-block-heading\">Company Announcements<\/h3>\n\n\n\n<div class=\"wp-btn-head display-none\">\n<a class=\"wp-btn click-zoom btn-cp\" href=\"https:\/\/player.vimeo.com\/video\/755323665\" data-target=\"latest-investor-briefing\">Watch Video<\/a>\n<a class=\"wp-btn\" href=\"#investor-briefing\">Book into the next Webcast<\/a>\n<\/div>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm2b6f69\" class=\"wp-block-gutentor-m4-col col-gm2b6f69 gutentor-single-column  grid-lg-4 grid-md-12 grid-12 display-none\"><div id=\"section-gm2b6f69\" class=\"section-gm2b6f69 gutentor-col-wrap\">\n<div class=\"wpb_wrapper\"><p><img decoding=\"async\" class=\"ceo-img prescient\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg\" alt=\" Steven Yatomi-Clarke\"><\/p><\/div>\n\n\n\n<h3 class=\"has-text-align-left has-text-color wp-block-heading\" style=\"color:#53d443\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">Steven Yatomi-Clarke<\/mark><\/h3>\n\n\n\n<p class=\"has-text-align-left has-white-color has-text-color\">CEO and Managing Director<\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n\n\n\n<section id=\"gm39a7f8c\" class=\"wp-block-gutentor-m3 alignfull section-gm39a7f8c gutentor-module gutentor-container-cover has-color-bg has-custom-bg wp_menu\"><div class=\"grid-container\">\n<section id=\"gmbee3818\" class=\"wp-block-gutentor-m4 section-gmbee3818 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm1922a5\" class=\"wp-block-gutentor-m4-col col-gm1922a5 gutentor-single-column  grid-lg-12 grid-md-12 grid-12 list-menu\"><div id=\"section-gm1922a5\" class=\"section-gm1922a5 gutentor-col-wrap\">\n<ul class=\"wp-block-list\"><li><a href=\"#updates\">View Announcements<\/a><\/li><li><a href=\"#investor-briefing\">Book Into Next Session<\/a><\/li><li><div class=\"popup-form\" id=\"id\">\n\t\n\t\t<button class=\"book\" style=\"width:auto;\">CONTACT US<\/button>\n<\/div><\/li><\/ul>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n\n\n\n<section id=\"gm57d4f4a\" class=\"wp-block-gutentor-m3 alignwide section-gm57d4f4a gutentor-module gutentor-container-cover has-color-bg has-custom-bg\"><div class=\"grid-container\">\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<section id=\"gmf76e157\" class=\"wp-block-gutentor-m4 section-gmf76e157 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm737103\" class=\"wp-block-gutentor-m4-col col-gm737103 gutentor-single-column  grid-lg-2 grid-md-12 grid-12\"><div id=\"section-gm737103\" class=\"section-gm737103 gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gm9cac44\" class=\"wp-block-gutentor-m4-col col-gm9cac44 gutentor-single-column  grid-lg-8 grid-md-12 grid-12\"><div id=\"section-gm9cac44\" class=\"section-gm9cac44 gutentor-col-wrap\">\n<div class=\"video-popup text-center rel\" class=\"wp-block-myblock-popup\"><img decoding=\"async\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-615-1-3.png\"\/><a class=\"click-zoom\" href=\"https:\/\/player.vimeo.com\/video\/755356204\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"54\" height=\"52\" viewBox=\"0 0 54 52\"><g fill=\"none\" fill-rule=\"evenodd\" stroke=\"none\" stroke-width=\"1\" opacity=\"0.9\"><g fill=\"#FFF\" fill-rule=\"nonzero\" transform=\"translate(-656 -2075)\"><g transform=\"translate(113 1901)\"><g transform=\"translate(0 91)\"><g transform=\"translate(390)\"><path d=\"M180 83.008c-14.378 0-26.075 11.66-26.075 25.992s11.697 25.992 26.075 25.992 26.075-11.66 26.075-25.992S194.378 83.008 180 83.008zm10.575 26.679l-16.822 11.738a.841.841 0 01-1.323-.687V97.262c0-.313.174-.6.452-.744a.845.845 0 01.871.057l16.822 11.738a.836.836 0 010 1.374z\"><\/path><\/g><\/g><\/g><\/g><\/g><\/svg><\/a><\/div>\n\n\n\n<a style=\"display:none;\" class=\"click-zoom btn-cp\" href=\"https:\/\/player.vimeo.com\/video\/755356204\" data-target=\"four-major\">Watch Video<\/a><script>jQuery(document).ready(function($) {\n$( window ).load(function() {\n\tvar url = location.hash;\n\tconsole.log('get', url);\n\t$('.click-zoom').each(function(){\n\t\tvar eEctive = $(this).attr('data-target');\n\t\tvar active = \"#\"+eEctive;\n\t\tconsole.log('active', active);\n\t\tif(url == active)\n\t\t{\n\t\t\tconsole.log('test');\n\t\t\t$(this).click();\n\t\t}\n\t})\n});\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmf1c04d\" class=\"wp-block-gutentor-m4-col col-gmf1c04d gutentor-single-column  grid-lg-2 grid-md-12 grid-12\"><div id=\"section-gmf1c04d\" class=\"section-gmf1c04d gutentor-col-wrap\"><\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"updates\" class=\"wp-block-gutentor-m4 section-gm12b5cb9 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm0985d1\" class=\"wp-block-gutentor-m4-col col-gm0985d1 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm0985d1\" class=\"section-gm0985d1 gutentor-col-wrap\">\n<h3 class=\"fz30 has-text-color wp-block-heading\" style=\"color:#40474f\">Announcements<\/h3>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm71c49b5\" class=\"wp-block-gutentor-m4 alignwide section-gm71c49b5 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm52543c\" class=\"wp-block-gutentor-m4-col col-gm52543c gutentor-single-column  grid-lg-6 grid-md-12 grid-12 cp-left video-anno\"><div id=\"section-gm52543c\" class=\"section-gm52543c gutentor-col-wrap\">\n<div class=\"video-popup text-center rel\" class=\"wp-block-myblock-popup\"><img decoding=\"async\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-616.png\"\/><a class=\"click-zoom\" href=\"https:\/\/player.vimeo.com\/video\/755353025\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"54\" height=\"52\" viewBox=\"0 0 54 52\"><g fill=\"none\" fill-rule=\"evenodd\" stroke=\"none\" stroke-width=\"1\" opacity=\"0.9\"><g fill=\"#FFF\" fill-rule=\"nonzero\" transform=\"translate(-656 -2075)\"><g transform=\"translate(113 1901)\"><g transform=\"translate(0 91)\"><g transform=\"translate(390)\"><path d=\"M180 83.008c-14.378 0-26.075 11.66-26.075 25.992s11.697 25.992 26.075 25.992 26.075-11.66 26.075-25.992S194.378 83.008 180 83.008zm10.575 26.679l-16.822 11.738a.841.841 0 01-1.323-.687V97.262c0-.313.174-.6.452-.744a.845.845 0 01.871.057l16.822 11.738a.836.836 0 010 1.374z\"><\/path><\/g><\/g><\/g><\/g><\/g><\/svg><\/a><\/div>\n\n\n\n<p>Unveiling of <strong>CellPryme-A adjuvant<\/strong>, designed to be administered to cancer patients to address the hostile tumour microenvironment that cellular immunotherapies face, thereby enhancing the ability of those therapies to kill cancer cells and improve host survival. <br><strong><a href=\"https:\/\/yourir.info\/resources\/3dd816e0350bdd55\/announcements\/ptx.asx\/3A602938\/PTX_PTX_unveils_CellPryme-A_to_boost_CAR-T_performance.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Click here<\/a> to view the ASX announcement.<\/strong><\/p>\n\n\n\n<a style=\"display:none;\" class=\"click-zoom btn-cp\" href=\"https:\/\/player.vimeo.com\/video\/755353025\" data-target=\"unveiling-cellpryme-a\">Watch Video<\/a>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm113b3e\" class=\"wp-block-gutentor-m4-col col-gm113b3e gutentor-single-column  grid-lg-6 grid-md-12 grid-12 cp-right video-anno\"><div id=\"section-gm113b3e\" class=\"section-gm113b3e gutentor-col-wrap\">\n<div class=\"video-popup text-center rel\" class=\"wp-block-myblock-popup\"><img decoding=\"async\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-612.png\"\/><a class=\"click-zoom\" href=\"https:\/\/player.vimeo.com\/video\/755357534\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"54\" height=\"52\" viewBox=\"0 0 54 52\"><g fill=\"none\" fill-rule=\"evenodd\" stroke=\"none\" stroke-width=\"1\" opacity=\"0.9\"><g fill=\"#FFF\" fill-rule=\"nonzero\" transform=\"translate(-656 -2075)\"><g transform=\"translate(113 1901)\"><g transform=\"translate(0 91)\"><g transform=\"translate(390)\"><path d=\"M180 83.008c-14.378 0-26.075 11.66-26.075 25.992s11.697 25.992 26.075 25.992 26.075-11.66 26.075-25.992S194.378 83.008 180 83.008zm10.575 26.679l-16.822 11.738a.841.841 0 01-1.323-.687V97.262c0-.313.174-.6.452-.744a.845.845 0 01.871.057l16.822 11.738a.836.836 0 010 1.374z\"><\/path><\/g><\/g><\/g><\/g><\/g><\/svg><\/a><\/div>\n\n\n\n<p>Strategic collaboration with <strong>MD Anderson Cancer Center<\/strong>, the largest cancer centre in the US, to develop unique blood cancer binders for OmniCAR. The agreement combines Prescient\u2019s modular \u201cplug and play\u201d CAR platform with an undisclosed, proprietary binder discovered by MD Anderson\u2019s ECLIPSE platform. <br><strong><a href=\"https:\/\/yourir.info\/resources\/3dd816e0350bdd55\/announcements\/ptx.asx\/3A601703\/PTX_PTX_strategic_collaboration_with_MD_Anderson_Cancer_Center.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Click here<\/a> to view the ASX announcement.<\/strong><\/p>\n\n\n\n<a style=\"display:none;\" class=\"click-zoom btn-cp\" href=\"https:\/\/player.vimeo.com\/video\/755357534\" data-target=\"md-anderson-strategic-collaboration\">Watch Video<\/a>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gmc155594\" class=\"wp-block-gutentor-m4 section-gmc155594 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm0dc5f5\" class=\"wp-block-gutentor-m4-col col-gm0dc5f5 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm0dc5f5\" class=\"section-gm0dc5f5 gutentor-col-wrap\">\n<p><span style=\"font-size: 12pt;\"><strong><span style=\"color: #ff446e;\">Like these videos? <span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"#investor-briefing\"><span style=\"text-decoration: underline;\">Click here<\/span><\/a><\/span> to join our next investor briefing to learn more about Prescient Therapeutics <\/span><\/strong><\/span><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm002a9eb\" class=\"wp-block-gutentor-m4 alignwide section-gm002a9eb gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm7c7719\" class=\"wp-block-gutentor-m4-col col-gm7c7719 gutentor-single-column  grid-lg-6 grid-md-12 grid-12 cp-left video-anno\"><div id=\"section-gm7c7719\" class=\"section-gm7c7719 gutentor-col-wrap\">\n<div class=\"video-popup text-center rel\" class=\"wp-block-myblock-popup\"><img decoding=\"async\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-604-1.png\"\/><a class=\"click-zoom\" href=\"https:\/\/player.vimeo.com\/video\/755354692\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"54\" height=\"52\" viewBox=\"0 0 54 52\"><g fill=\"none\" fill-rule=\"evenodd\" stroke=\"none\" stroke-width=\"1\" opacity=\"0.9\"><g fill=\"#FFF\" fill-rule=\"nonzero\" transform=\"translate(-656 -2075)\"><g transform=\"translate(113 1901)\"><g transform=\"translate(0 91)\"><g transform=\"translate(390)\"><path d=\"M180 83.008c-14.378 0-26.075 11.66-26.075 25.992s11.697 25.992 26.075 25.992 26.075-11.66 26.075-25.992S194.378 83.008 180 83.008zm10.575 26.679l-16.822 11.738a.841.841 0 01-1.323-.687V97.262c0-.313.174-.6.452-.744a.845.845 0 01.871.057l16.822 11.738a.836.836 0 010 1.374z\"><\/path><\/g><\/g><\/g><\/g><\/g><\/svg><\/a><\/div>\n\n\n\n<p><strong>A production contract with Q-Gen<\/strong>, a specialist cell manufacturing company, to produce first OmniCAR T-cells for upcoming clinical trials, thereby helping Prescient progress towards its first in-human studies of OmniCAR \u2013 an important milestone for the company. <br><strong><a href=\"https:\/\/yourir.info\/resources\/3dd816e0350bdd55\/announcements\/ptx.asx\/3A599113\/PTX_PTX_OmniCAR_cell_manufacturing_contract_for_clinical_trials.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Click here<\/a> to view the ASX announcement.<\/strong><\/p>\n\n\n\n<a style=\"display:none;\" class=\"click-zoom btn-cp\" href=\"https:\/\/player.vimeo.com\/video\/755354692\" data-target=\"q-gen-manufacturing-agreement\">Watch Video<\/a>\n<\/div><\/div>\n\n\n\n<div id=\"col-gma4d0de\" class=\"wp-block-gutentor-m4-col col-gma4d0de gutentor-single-column  grid-lg-6 grid-md-12 grid-12 cp-right video-anno\"><div id=\"section-gma4d0de\" class=\"section-gma4d0de gutentor-col-wrap\">\n<div class=\"video-popup text-center rel\" class=\"wp-block-myblock-popup\"><img decoding=\"async\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-614.png\"\/><a class=\"click-zoom\" href=\"https:\/\/player.vimeo.com\/video\/755358687\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"54\" height=\"52\" viewBox=\"0 0 54 52\"><g fill=\"none\" fill-rule=\"evenodd\" stroke=\"none\" stroke-width=\"1\" opacity=\"0.9\"><g fill=\"#FFF\" fill-rule=\"nonzero\" transform=\"translate(-656 -2075)\"><g transform=\"translate(113 1901)\"><g transform=\"translate(0 91)\"><g transform=\"translate(390)\"><path d=\"M180 83.008c-14.378 0-26.075 11.66-26.075 25.992s11.697 25.992 26.075 25.992 26.075-11.66 26.075-25.992S194.378 83.008 180 83.008zm10.575 26.679l-16.822 11.738a.841.841 0 01-1.323-.687V97.262c0-.313.174-.6.452-.744a.845.845 0 01.871.057l16.822 11.738a.836.836 0 010 1.374z\"><\/path><\/g><\/g><\/g><\/g><\/g><\/svg><\/a><\/div>\n\n\n\n<p>The <strong>US FDA granting \u2018Orphan Drug Designation\u2019<\/strong> to Prescient\u2019s PTX-100 for treating peripheral T-cell lymphomas \u2013 a disease with high unmet need. The benefits of an Orphan Drug Designation are considerable and include guaranteed market exclusivity of seven years from granting of regulatory approval. <br><strong><a href=\"https:\/\/yourir.info\/resources\/3dd816e0350bdd55\/announcements\/ptx.asx\/3A597270\/PTX_US_FDA_Grants_Orphan_Drug_Designation_to_PTX-100_for_PTCL.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Click here<\/a> to view the ASX announcement.&nbsp;<\/strong><\/p>\n\n\n\n<a style=\"display:none;\" class=\"click-zoom btn-cp\" href=\"https:\/\/player.vimeo.com\/video\/755358687\" data-target=\"us-dfa-grants-orphan-drug\">Watch Video<\/a>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n\n\n\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gm0b23d68 gutentor-module gutentor-container-cover has-image-bg has-custom-bg webca\"><div class=\"grid-container\">\n<h2 class=\"has-text-align-left fz36 fz30 has-white-color has-text-color has-large-font-size wp-block-heading\">Live Investor Briefing<\/h2>\n\n\n\n<h3 class=\"has-text-align-left has-text-color wp-block-heading\" style=\"color:#53d443;font-size:23px\">Prescient Therapeutics (ASX: PTX)<\/h3>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<section id=\"fsz\" class=\"wp-block-gutentor-m4 section-gmd80d9fc gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmdc5f1b\" class=\"wp-block-gutentor-m4-col col-gmdc5f1b gutentor-single-column  grid-lg-7 grid-md-6 grid-12 text-l\"><div id=\"section-gmdc5f1b\" class=\"section-gmdc5f1b gutentor-col-wrap\">\n<h3 class=\"border-bottom fz20 has-white-color has-text-color wp-block-heading\" style=\"font-size:28px\"><strong>Tuesday, 4th October 12pm (AEDT)<\/strong><\/h3>\n\n\n\n<p class=\"has-white-color has-text-color\">Please join Prescient CEO and managing director Steven Yatomi-Clarke for an investor briefing.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\"><strong>In this session, Steven will discuss:<\/strong><\/p>\n\n\n\n<ul class=\"disc wp-block-list\"><li><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">How PTX is taking the cancer treatment conversation from \u2018fight\u2019 to \u2018cure\u2019<\/mark><\/li><li><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">How the company can potentially make any CAR-T developer\u2019s therapies more effective, cheaper and safer<\/mark><\/li><li><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">How its modular platform allows PTX to partner with any CAR-T developer giving them a \u2018shovels to the gold rush\u2019 position<\/mark><\/li><\/ul>\n\n\n\n<p><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">It will be a fascinating look into why Prescient\u2019s highly scalable business model gives them multiple shots on goal in oncology.<\/mark><\/p>\n\n\n\n<p><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">This is a live and interactive online session, and participants are encouraged to ask questions.\u00a0<\/mark><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color\"><strong style=\"color: #53D443;\">Spots are limited, so secure yours toda<strong>y.<\/strong><\/strong><\/mark><\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm93f8b0\" class=\"wp-block-gutentor-m4-col col-gm93f8b0 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm93f8b0\" class=\"section-gm93f8b0 gutentor-col-wrap\">        <div class=\"enouvo-form  show-text \">\n            <h4 class=\"form-title\" style=\"color:#ffce06\">Attend the session<\/h4>            <!--[if lte IE 8]>\n            <script charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2-legacy.js\"><\/script>\n            <![endif]-->\n            <script charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2.js\"><\/script>\n            <script data-hubspot-rendered=\"true\">hbspt.forms.create({\n                portalId: \"7664250\",\n                formId: \"1e785d03-161c-49c5-a62a-27d007ffd0ba\",\n                goToWebinarWebinarKey: '',\n                    onFormSubmitted: function($form) {\n                        jQuery('.hypelinkbkt, .byclick').hide();\n                    }\n            });<\/script>\n                        \n                            <a id=\"hypelinkbkt\" class=\"hypelinkbkt\" target=\"blank\" rel=\"noopener noreferrer\">What is a 708 investor?<\/a>\n            <div class=\"byclick\"><p>By clicking submit, I agree to the terms of the <a href=\"https:\/\/reachmarkets.com.au\/financial-services-guide\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Reach Markets Financial Services Guide<\/strong><\/a>\u00a0that includes the <a href=\"https:\/\/reachmarkets.com.au\/privacy-reach\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Privacy Statement.<\/strong><\/a> Reach Corporate provides Corporate Advisory Services to Prescient Therapeutics Limited and has been engaged by them to manage their investor communications including managing this offer and may receive fees for its services.<\/p><\/div>\n                                    <\/div>\n            \n        \n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n\n\n\n<section id=\"gm3b60033\" class=\"wp-block-gutentor-m3 alignwide section-gm3b60033 gutentor-module gutentor-container-cover custom-fullwidth author\"><div class=\"grid-container\">\n<section id=\"gm9caf41d\" class=\"wp-block-gutentor-m4 section-gm9caf41d gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm143c18\" class=\"wp-block-gutentor-m4-col col-gm143c18 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm143c18\" class=\"section-gm143c18 gutentor-col-wrap\">\n<h4 class=\"fz30 has-text-color wp-block-heading\" style=\"color:#012850;font-size:25px\">Featured Speaker<\/h4>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gmd40c1c2\" class=\"wp-block-gutentor-m4 section-gmd40c1c2 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmd6d126\" class=\"wp-block-gutentor-m4-col col-gmd6d126 gutentor-single-column  grid-lg-3 grid-md-5 grid-12\"><div id=\"section-gmd6d126\" class=\"section-gmd6d126 gutentor-col-wrap\">\n<div class=\"wpb_wrapper\"><p><img decoding=\"async\" class=\"ceo-img\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg\" alt=\" Michael Davidson\"><\/p><\/div>\n\n\n\n<style>\n.enouvo-form .form-title {\n    font-size: 24px;\n}\n.border-bottom{border-bottom: 7px solid #53D443;\n    display: inline-block;\n    padding-bottom: 10px;\n    margin-bottom: 15px;}\n.wpb_wrapper p{\nmargin-top: 0px;}\n.author .grid-container{\nwidth:1170px;\nmax-width: 100%;\n}\n.author{\n    padding-top: 10px;\n    background: #fff;\n    padding-bottom: 45px;\n    max-width: 100vw;\n    width: 100vw;\n    left: 50%;\n    margin-left: -50vw;\n}\n.ceo-img {\n    width: 100%;\n    border-radius: 50%;\nfilter: drop-shadow(4px 4px 20px rgba(0, 0, 0, 0.25));\n}\n.infor {\n    color: #fff;\n    overflow: hidden;\n    padding-top: 0px;\n    padding-left: 20px;\n}\n.infor h3 {\n    font-weight: bold;\n    margin-bottom: 10px;\n    color: #fff;\n    font-size: 25px;\n}\n.infor p {\n    font-size: 16px !important;\n}\n@media only screen and (max-width: 1024px){\n.infor h3 {\n    font-size: 16px;\n}\n}\n\n.enouvo-form .byclick strong {\n    color: #203865;\n}\n.custom-bg{    background-image: linear-gradient( rgba(0, 0, 0, .56), rgba(0, 0, 0, .56)), url(\/wp-content\/uploads\/2021\/04\/bg-ibv-min.jpg);}div#section-gmecaa61 { color: #fff; font-size: 16px!important; }div#col-gmecaa61 ul {\n    list-style: disc;\n    padding-left: 40px;\n    font-size: 16px;\n}\n\ndiv#col-gmecaa61 li {\n    margin-bottom:10px;\n}div#col-gmecaa61 ul { margin-bottom: 16px; } div#col-gmecaa61 p { line-height: 28.8px!important; margin-bottom: 16px; }h4.form-title { font-size: 24px; color: #3f4346!important; line-height: 34px; text-align: center; } .enouvo-form.show-text { background: rgba(255,255,255,.8); border-radius:6px; }.form-control, .hbspt-form input[type=email], .hbspt-form input[type=text], input[type=number], textarea, input[type=tel], select { border: 1px solid #ccd0d4!important; max-height: 45px !important; color: #212529 !important; font-family: \"Montserrat\",sans-serif; }.hbspt-form input.hs-button.primary.large { color: #3F4346!important; border: none; background: #FECC31!important; -webkit-transition: all .2s ease-in-out; transition: all .2s ease-in-out; text-transform: capitalize; font-size: 16px!important; }.hbspt-form input.hs-button.primary.large:hover { opacity: 0.7; } .enouvo-form .hypelinkbkt, .enouvo-form .byclick, .enouvo-form .byclick strong { color: #3F4346; } input:focus, button:focus, textarea:focus, select:focus { border-color: #000; } a#hypelinkbkt:hover { opacity: 0.7; }.hbspt-form select:focus, .hbspt-form input[type=text]:focus, .hbspt-form input[type=tel]:focus, .hbspt-form input[type=email]:focus, .hbspt-form input[type=number]:focus { border-color: #ccd0d4!important; } .hbspt-form .field { margin-bottom: 10px; } .form-control, .hbspt-form input[type=email], .hbspt-form input[type=text], input[type=number], textarea, input[type=tel], select { margin-bottom: 0; }.author {  }.text-l ul { list-style: disc; padding-left: 25px; color: #fff; } .text-l ul li { margin-bottom: 15px; }.enouvo-form .form-title { color: #ffce06!important; text-align: left; } .enouvo-form.show-text { background: #fff; } .author { padding-top: 10px; padding-bottom: 45px; } div#section-gm8f7e98 { font-size: 15px; } section#fsz p, section#fsz li { font-size: 16px; } .enouvo-form .hypelinkbkt { color: #ffce06; }.form-sidebar .hbspt-form {\n    margin-top: 0px!important;\n}\n<\/style>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmea792f\" class=\"wp-block-gutentor-m4-col col-gmea792f gutentor-single-column  grid-lg-9 grid-md-7 grid-12 bioa\"><div id=\"section-gmea792f\" class=\"section-gmea792f gutentor-col-wrap\">\n<h3 class=\"has-text-color wp-block-heading\" style=\"color:#0089c4;font-size:32px\">Steven Yatomi-Clarke<\/h3>\n\n\n\n<p class=\"has-black-color has-text-color has-normal-font-size\">CEO and Managing Director<\/p>\n\n\n\n<p><span style=\"color: #000; font-size: 16px; margin-top: 21px; display: block;\">Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.<\/span><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm3119cf5\" class=\"wp-block-gutentor-m4 section-gm3119cf5 gutentor-module gutentor-advanced-columns d-none\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gma3446c\" class=\"wp-block-gutentor-m4-col col-gma3446c gutentor-single-column  grid-lg-3 grid-md-5 grid-12\"><div id=\"section-gma3446c\" class=\"section-gma3446c gutentor-col-wrap\">\n<div class=\"wpb_wrapper\"><p><img decoding=\"async\" class=\"ceo-img\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Rebecca-Lim.jpg\" alt=\"Dr Rebecca Lim\"><\/p><\/div>\n\n\n\n<style>\n.enouvo-form .form-title {\n    font-size: 24px;\n}\n.border-bottom{border-bottom: 7px solid #53D443;\n    display: inline-block;\n    padding-bottom: 10px;\n    margin-bottom: 15px;}\n.wpb_wrapper p{\nmargin-top: 0px;}\n.author .grid-container{\nwidth:1170px;\nmax-width: 100%;\n}\n.author{\n    padding-top: 10px;\n    background: #fff;\n    padding-bottom: 45px;\n    max-width: 100vw;\n    width: 100vw;\n    left: 50%;\n    margin-left: -50vw;\n}\n.ceo-img {\n    width: 100%;\n    border-radius: 50%;\nfilter: drop-shadow(4px 4px 20px rgba(0, 0, 0, 0.25));\n}\n.infor {\n    color: #fff;\n    overflow: hidden;\n    padding-top: 0px;\n    padding-left: 20px;\n}\n.infor h3 {\n    font-weight: bold;\n    margin-bottom: 10px;\n    color: #fff;\n    font-size: 25px;\n}\n.infor p {\n    font-size: 16px !important;\n}\n@media only screen and (max-width: 1024px){\n.infor h3 {\n    font-size: 16px;\n}\n}\n\n.enouvo-form .byclick strong {\n    color: #203865;\n}\n.custom-bg{    background-image: linear-gradient( rgba(0, 0, 0, .56), rgba(0, 0, 0, .56)), url(\/wp-content\/uploads\/2021\/04\/bg-ibv-min.jpg);}div#section-gmecaa61 { color: #fff; font-size: 16px!important; }div#col-gmecaa61 ul {\n    list-style: disc;\n    padding-left: 40px;\n    font-size: 16px;\n}\n\ndiv#col-gmecaa61 li {\n    margin-bottom:10px;\n}div#col-gmecaa61 ul { margin-bottom: 16px; } div#col-gmecaa61 p { line-height: 28.8px!important; margin-bottom: 16px; }h4.form-title { font-size: 24px; color: #3f4346!important; line-height: 34px; text-align: center; } .enouvo-form.show-text { background: rgba(255,255,255,.8); border-radius:6px; }.form-control, .hbspt-form input[type=email], .hbspt-form input[type=text], input[type=number], textarea, input[type=tel], select { border: 1px solid #ccd0d4!important; max-height: 45px !important; color: #212529 !important; font-family: \"Montserrat\",sans-serif; }.hbspt-form input.hs-button.primary.large { color: #3F4346!important; border: none; background: #FECC31!important; -webkit-transition: all .2s ease-in-out; transition: all .2s ease-in-out; text-transform: capitalize; font-size: 16px!important; }.hbspt-form input.hs-button.primary.large:hover { opacity: 0.7; } .enouvo-form .hypelinkbkt, .enouvo-form .byclick, .enouvo-form .byclick strong { color: #3F4346; } input:focus, button:focus, textarea:focus, select:focus { border-color: #000; } a#hypelinkbkt:hover { opacity: 0.7; }.hbspt-form select:focus, .hbspt-form input[type=text]:focus, .hbspt-form input[type=tel]:focus, .hbspt-form input[type=email]:focus, .hbspt-form input[type=number]:focus { border-color: #ccd0d4!important; } .hbspt-form .field { margin-bottom: 10px; } .form-control, .hbspt-form input[type=email], .hbspt-form input[type=text], input[type=number], textarea, input[type=tel], select { margin-bottom: 0; }.author {  }.text-l ul { list-style: disc; padding-left: 25px; color: #fff; } .text-l ul li { margin-bottom: 15px; }.enouvo-form .form-title { color: #ffce06!important; text-align: left; } .enouvo-form.show-text { background: #fff; } .author { padding-top: 10px; padding-bottom: 45px; } div#section-gm8f7e98 { font-size: 15px; } section#fsz p, section#fsz li { font-size: 16px; } .enouvo-form .hypelinkbkt { color: #ffce06; }.form-sidebar .hbspt-form {\n    margin-top: 0px!important;\n}\n<\/style>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm9bff7e\" class=\"wp-block-gutentor-m4-col col-gm9bff7e gutentor-single-column  grid-lg-9 grid-md-7 grid-12 bioa\"><div id=\"section-gm9bff7e\" class=\"section-gm9bff7e gutentor-col-wrap\">\n<h3 class=\"has-text-color wp-block-heading\" style=\"color:#0089c4;font-size:32px\">Dr Rebecca Lim<\/h3>\n\n\n\n<p class=\"has-black-color has-text-color has-normal-font-size\">Senior Vice President of Scientific Affairs<\/p>\n\n\n\n<p><span style=\"color: #000; font-size: 16px; margin-top: 21px; display: block;\">Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.<\/span><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n<div class=\"form-sidebar\"><a class=\"closes\" style=\"cursor: pointer;\"><img decoding=\"async\" src=\"https:\/\/prescienttherapeutics-rebuild.investorportal.com.au\/wp-content\/uploads\/2022\/07\/close-btn.svg\"><\/a><div style=\"padding: 0 0 0 0; position: relative;\">\r\n<h2 class=\"the-latest-news\" style=\"color: #0089C4; text-align: left; font-size: 24px!important; margin-bottom: 5px;\">Receive email updates<\/h2>\r\n\r\n<!-- Hotjar Tracking Code for https:\/\/template.reachmarkets.com.au\/investorportal\/ --> <script> (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2736440,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https:\/\/static.hotjar.com\/c\/hotjar-','.js?sv='); <\/script> <!--[if lte IE 8]> <script charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2-legacy.js\"><\/script> <![endif]--> <script  charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2.js\"><\/script> <script> hbspt.forms.create({ region: \"na1\", portalId: \"7664250\", formId: \"8be09ab6-f2b3-484c-8108-42cd66e3980d\", formInstanceId: \"slide\", onFormSubmitted: function($form) { jQuery('.byclick').hide(); gtag_report_conversion('#'); jQuery('.the-latest-news').text('Receive email updates'); } }); <\/script><a id=\"hypelinkbkt\" class=\"hypelinkbkt\" style=\"font-weight: 700; font-size: 14px;\" target=\"blank\" rel=\"noopener noreferrer\">What is a 708 investor?<\/a><p class=\"byclick\" style=\"font-size: 14px !important;margin-bottom: 0px;\">By submitting this form, I agree to the terms of the&nbsp;<a class=\"md-opjjpmhoiojifppkkcdabiobhakljdgm_doc\" href=\"https:\/\/reachmarkets.com.au\/financial-services-guide\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong style=\"font-size: 14px !important;\">Reach Markets Financial Services Guide<\/strong><\/a>&nbsp;that includes the&nbsp;<a class=\"md-opjjpmhoiojifppkkcdabiobhakljdgm_doc\" href=\"https:\/\/reachmarkets.com.au\/privacy-reach\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong style=\"font-size: 14px !important;\">Privacy Statement<\/strong><\/a>. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.<\/p>\r\n<\/div>\r\n<\/div><\/div>\n<\/div><\/section>\n\n\n\n<div id=\"id05\" class=\"modals\" style=\" overflow: auto !important; \">\n   <span onclick=\"document.getElementById('id05').style.display='none'\" class=\"closes\" title=\"Close Modal\">\u00d7<\/span>\n  \n  <div class=\"modal-content animate\">\n     \n  <div style=\"padding: 0 0 0 0; position: relative;\">\n<h2 class=\"the-latest-news\" style=\"color: #0089c4; text-align: left; font-size: 24px!important; margin-bottom: 10px !important;\">Contact us<\/h2><!-- [if lte IE 8]> <script charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2-legacy.js\"><\/script> <![endif]--> <script charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2.js\"><\/script> <script> hbspt.forms.create({ region: \"na1\", portalId: \"7664250\", formId: \"37f872e6-39f3-42e9-85f0-ceaf8a3d9cdc\", formInstanceId: \"slide\", onFormSubmitted: function($form) { jQuery('.byclick').hide(); gtag_report_conversion('#'); jQuery('.the-latest-news').text('Receive email updates'); } }); <\/script><a id=\"hypelinkbkt\" class=\"hypelinkbkt\" style=\"font-weight: bold; font-size: 14px;\" target=\"blank\" rel=\"noopener noreferrer\">What is a 708 investor?<\/a>\n<p class=\"byclick\" style=\"font-size: 14px !important; margin-bottom: 0px;\">By submitting this form, I agree to the terms of the&nbsp;<a class=\"md-opjjpmhoiojifppkkcdabiobhakljdgm_doc\" href=\"https:\/\/reachmarkets.com.au\/financial-services-guide\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong style=\"font-size: 14px !important;\">Reach Markets Financial Services Guide<\/strong><\/a>&nbsp;that includes the&nbsp;<a class=\"md-opjjpmhoiojifppkkcdabiobhakljdgm_doc\" href=\"https:\/\/reachmarkets.com.au\/privacy-reach\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong style=\"font-size: 14px !important;\">Privacy Statement<\/strong><\/a>. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.<\/p>\n\n<\/div>\n  <\/div>\n<\/div>\n\n\n\n<section id=\"gmb0109da\" class=\"wp-block-gutentor-m3 section-gmb0109da gutentor-module gutentor-container-cover has-color-bg has-custom-bg dic\"><div class=\"grid-container\">\n<p><strong>Disclaimer and safe harbor<\/strong><\/p>\n\n\n\n<p><em>Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited (\u201cPrescient\u201d or the \u201cCompany\u201d), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words \u2018estimate\u2019, \u2018project\u2019, \u2018intend\u2019, \u2018expect\u2019, \u2018plan\u2019, \u2018believe\u2019, \u2018guidance\u2019, and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management\u2019s current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.<\/em><\/p>\n\n\n\n<p><br><em>Certain statements contained in this document, including, without limitation, statements containing the words \u201cbelieves,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d and words of similar import, constitute \u201cforward-looking statements.\u201d Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.<\/em><\/p>\n\n\n\n<p><br><em>This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.<\/em><\/p>\n\n\n\n<p><br><em>The contents of this document are confidential information of Prescient. These contents are made available on a \u2018for your eyes only\u2019 basis to the person to whom it was sent by Prescient. The purpose of the disclosure is to facilitate commercial and confidential discussions between the disclosee and Prescient. It should not be forwarded without the prior written consent of the Company.<\/em>&nbsp;<\/p>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"<p>\u00d7 Contact us What is a 708 investor? By submitting this form, I agree to the terms of the&nbsp;Reach Markets Financial Services Guide&nbsp;that includes the&nbsp;Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-28616","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics - PTX Therapeutics\" \/>\n<meta property=\"og:description\" content=\"\u00d7 Contact us What is a 708 investor? By submitting this form, I agree to the terms of the&nbsp;Reach Markets Financial Services Guide&nbsp;that includes the&nbsp;Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-30T04:32:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/\",\"name\":\"Prescient Therapeutics - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg\",\"datePublished\":\"2022-09-29T07:44:29+00:00\",\"dateModified\":\"2022-09-30T04:32:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg\",\"width\":300,\"height\":300,\"caption\":\"29\/03\/2019 Prescient Therapeutics CEO Steven Yatomi-Clarke in Melbourne. picture : David Geraghty \/ The Australian.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics - PTX Therapeutics","og_description":"\u00d7 Contact us What is a 708 investor? By submitting this form, I agree to the terms of the&nbsp;Reach Markets Financial Services Guide&nbsp;that includes the&nbsp;Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/","og_site_name":"PTX Therapeutics","article_modified_time":"2022-09-30T04:32:48+00:00","og_image":[{"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/","name":"Prescient Therapeutics - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg","datePublished":"2022-09-29T07:44:29+00:00","dateModified":"2022-09-30T04:32:48+00:00","breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/04\/SYC-cropped.jpg","width":300,"height":300,"caption":"29\/03\/2019 Prescient Therapeutics CEO Steven Yatomi-Clarke in Melbourne. picture : David Geraghty \/ The Australian."},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/company-announcements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/28616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=28616"}],"version-history":[{"count":108,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/28616\/revisions"}],"predecessor-version":[{"id":28801,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/28616\/revisions\/28801"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=28616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}